NDAINHALATIONSOLUTION
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
6/8 — Strong
YUPELRI (revefenacin) by Viatris (2) is cholinergic antagonists [moa]. Approved for chronic obstructive pulmonary disease. First approved in 2018.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUPELRI (revefenacin) is an inhaled anticholinergic bronchodilator approved in 2018 for maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by blocking cholinergic receptors in airway smooth muscle to improve lung function. The drug is delivered as a nebulized solution for once-daily dosing.
$4MPart D
Peak13.5 years to LOEProduct is at peak lifecycle stage with limited Part D adoption, suggesting mature market positioning and potential organizational efficiency rather than growth-phase expansion.
Mechanism of Action
Cholinergic Antagonists
Pharmacologic Class:
Anticholinergic
Indications (1)
Clinical Trials (3)
Revefenacin in Acute Respiratory Insufficiency in COPD
Started Nov 2020
21 enrolled
COPDAcute Respiratory Failure
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
Started May 2018
122 enrolled
Chronic Obstructive Pulmonary Disease (COPD)
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
Started Mar 2017
207 enrolled
Chronic Obstructive Pulmonary Disease, COPDLow Peak Inspiratory Flow Rate (PIFR)
Worked on YUPELRI at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.